TherapeuticsMD (TXMD) Total Non-Current Liabilities (2012 - 2026)

TherapeuticsMD (TXMD) has reported Total Non-Current Liabilities for 11 consecutive years, with $9.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities fell 8.25% year-over-year to $9.5 million; the trailing twelve-month figure through Jun 2026 stood at $9.5 million (down 8.25% YoY), and the FY2025 full-year result was $9.9 million, down 7.48% from the prior year.
• Total Non-Current Liabilities retreated to $9.5 million in Q2 2026 per TXMD's latest filing, from $9.7 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $272.7 million in Q1 2022 and bottomed at $9.5 million in Q2 2026.
• Historically, Total Non-Current Liabilities has averaged $48.4 million across 5 years, with a median of $12.3 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities slumped 90.29% in 2023, then slipped 7.48% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $54.2 million in 2022, then plunged by 75.31% to $13.4 million in 2023, then dropped by 20.01% to $10.7 million in 2024, then declined by 7.48% to $9.9 million in 2025, then dropped by 3.87% to $9.5 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $9.5 million, $9.7 million, and $9.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.